Advertisement

Topics

Kiadis Will Marry Its T-Cell Platform to Cytosen’s NK-Cell Platform in All-Stock Deal

20:00 EDT 16 Apr 2019 | BioSpace

The combination of the two companies will create a leader in cell-based cancer immunotherapy, Kiadis said. It also further expands Kiadis’ toehold in the United States.

Original Article: Kiadis Will Marry Its T-Cell Platform to Cytosen’s NK-Cell Platform in All-Stock Deal

NEXT ARTICLE

More From BioPortfolio on "Kiadis Will Marry Its T-Cell Platform to Cytosen’s NK-Cell Platform in All-Stock Deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...